Patents by Inventor Klaus Nickisch

Klaus Nickisch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190153018
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Application
    Filed: July 18, 2018
    Publication date: May 23, 2019
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • Patent number: 10273263
    Abstract: Various prodrug compounds having the general structure: Active agent—(acid)-(linker)—SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 30, 2019
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Publication number: 20190117670
    Abstract: Described herein are progestin compounds that have extended release rates and that can be used without an estrogen to produce a contraceptive state.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 25, 2019
    Inventors: Gulzar Ahmed, Frederick Meece, Hareesh Nair, Klaus Nickisch
  • Patent number: 10053485
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: August 21, 2018
    Assignee: Evestra, Inc.
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • Publication number: 20180155386
    Abstract: Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
    Type: Application
    Filed: December 4, 2017
    Publication date: June 7, 2018
    Inventors: Klaus Nickisch, Kesavaram Narkunan, Baishakhi Debnath, Bindu Santhamma
  • Patent number: 9850273
    Abstract: Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 26, 2017
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Hareesh Nair, Walter Elger
  • Publication number: 20170349624
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Application
    Filed: August 24, 2017
    Publication date: December 7, 2017
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Publication number: 20170319833
    Abstract: Described herein is an intravaginal drug delivery system. In an embodiment the intravaginal drug delivery system includes a progestin and estrogen compound, and releases the active ingredients in a fixed physiological ratio over a prolonged period of time to produce a contraceptive state in a female.
    Type: Application
    Filed: February 13, 2017
    Publication date: November 9, 2017
    Inventors: Ze'ev Shaked, Klaus Nickisch, James DiNunzio, Feng Zhang, Marcelo Omelczuk
  • Patent number: 9745338
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 29, 2017
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Publication number: 20160279145
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Application
    Filed: March 22, 2016
    Publication date: September 29, 2016
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • Publication number: 20160159852
    Abstract: Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.
    Type: Application
    Filed: December 3, 2015
    Publication date: June 9, 2016
    Inventors: Klaus Nickisch, Bindu Santhamma, Hareesh Nair, Walter Elger
  • Patent number: 9096641
    Abstract: Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: August 4, 2015
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Walter Elger, Bindu Santhamma
  • Publication number: 20150018322
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Publication number: 20140364600
    Abstract: Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.
    Type: Application
    Filed: June 5, 2013
    Publication date: December 11, 2014
    Inventors: Klaus Nickisch, Walter Elger, Bindu Santhamma
  • Patent number: 8673968
    Abstract: Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: March 18, 2014
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, James Cessac, Kesavaram Narkunan, Baishakhi Das
  • Publication number: 20130123523
    Abstract: Described herein is a process for the synthesis of etonogestrel and desogestrel and intermediates used to form etonogestrel and desogestrel.
    Type: Application
    Filed: November 10, 2011
    Publication date: May 16, 2013
    Inventors: Klaus Nickisch, Bindu Santhamma
  • Publication number: 20130029953
    Abstract: Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
    Type: Application
    Filed: July 28, 2011
    Publication date: January 31, 2013
    Inventors: Klaus Nickisch, Kesavaram Narkunan, Baishakhi Debnath, Bindu Santhamma
  • Patent number: 8334375
    Abstract: Described herein are methods of making drospirenone. Also described are intermediate compounds that may be used to synthesis drospirenone.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: December 18, 2012
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Kirk Acosta, Bindu Santhamma
  • Patent number: 8222237
    Abstract: Described herein are 3-(6,6-ethylene-17?-hydroxy-3-oxo-17?-pregna-4-ene-17?-yl)propionic acid ?-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: July 17, 2012
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Pemmaraju Rao, Kesavaram Narkunan, James Cessac
  • Publication number: 20110250274
    Abstract: Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of estriol compounds. Embodiments described herein relate to rapidly disintegrating oral dosage formulations that disintegrate in the saliva of the buccal and/or sublingual and/or esophageal cavity. Oral dosage forms described herein relate to stabilized amorphous and nanocrystalline forms of the active ingredients of the formulations.
    Type: Application
    Filed: September 18, 2009
    Publication date: October 13, 2011
    Inventors: Ze'ev Shaked, Walter Elger, Klaus Nickisch